# Contemporary Practices for Management of Subclinical Atrial Fibrillation

## TL;DR

This paper reviews current practices for managing subclinical atrial fibrillation, focusing on whether patients should receive anticoagulation therapy to prevent complications.

## Contribution

The paper provides a literature review to guide individualized decision-making for anticoagulation in subclinical atrial fibrillation.

## Key findings

- Subclinical atrial fibrillation episodes are linked to potential clinical complications like stroke.
- Anticoagulation therapy decisions should be tailored to individual patient risk profiles.
- Further research is needed to identify which patients benefit most from treatment.

## Abstract

Subclinical atrial fibrillation (SCAF) episodes are frequently detected in patients with cardiac implantable electronic devices (CIEDs). These asymptomatic arrhythmias are increasingly recognized as potential harbingers of clinical atrial fibrillation and thromboembolic events. However, the management of SCAF—particularly regarding the use of oral anticoagulation (OAC)—remains controversial. This literature review (Medline, Scopus, Goggle scholar, Embase) focuses on using current literature and clinical studies to guide decision-making regarding anticoagulation therapy and other treatment options that can limit complications for patients with SCAF. The decision to initiate anticoagulation in patients with atrial high-rate episodes (AHREs) should be individualized, balancing stroke risk against bleeding potential. Ongoing research and post hoc analyses will further clarify which subgroups may benefit most from therapy, informing future guideline recommendations.